This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The paper, by a team from Imperial College London, concluded that the FDA gave the go ahead to 95% of the 89 products approved between 2010 and 2019 before EMA, with the Europeans trailing the Americans by a median of 241 days. Between 2012 and 2020, it averaged 3% each year, whereas Spain’s share, for example, had increased from 2.6%
Firms in the pharmaceutical industry – as with those in many advanced sectors – have become increasingly preoccupied with environmental, social and governance (ESG) goals in recent years. Household names are leading the way. Figure 1: Social media posts from pharmaceutical firms mentioning “environment”. Source: GlobalData.
Innovation S-curve for the pharmaceutical industry Lipase compositions is a key innovation area in pharmaceuticals Lipases belong to a class of hydrolase enzymes, which help in the hydrolysis of triglycerides and break them down into free fatty acids and glycerol.
Patent volumes related to ssRNA virus peptides Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Johnson & Johnson 419 Unlock company profile GSK 419 Unlock company profile C. J&J develops, manufactures, and sells pharmaceuticalproducts, medical devices, and consumer products.
In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.
Johnson & Johnson researches, develops, manufactures, and sells pharmaceuticalproducts, medical devices, and consumer products. ‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content